Seven Eight Capital’s bluebird bio BLUE Stock Holding History

Seven Eight Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,112	Closed	-$623K	–	588
2021 Q1	$623K	Hold	1,112	–	–	0.14%	233
2020 Q4	$623K	Buy	1,112 +718	+182%	+$455K	0.14%	236
2020 Q3	$275K	Buy	+394	New	+$307K	0.06%	465
2017 Q4	–	Sell	-966	Closed	-$1.72M	–	457
2017 Q3	$1.72M	Buy	+966	New	+$1.35M	0.21%	160
2016 Q2	–	Sell	-196	Closed	-$108K	–	540
2016 Q1	$108K	Buy	+196	New	+$120K	0.05%	376
2015 Q4	–	Sell	-162	Closed	-$180K	–	552
2015 Q3	$180K	Buy	162 +147	+980%	+$268K	0.16%	206
2015 Q2	$34K	Sell	15 -16	-52%	-$32.6K	0.04%	381
2015 Q1	$48K	Sell	31 -131	-81%	-$173K	0.08%	287
2014 Q4	$193K	Buy	+162	New	+$108K	0.32%	118

Other funds holding BLUE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Seven Eight Capital's BLUE Position: Q2 2021 in Review

Seven Eight Capital sold out of bluebird bio (BLUE) in Q2 2021, closing a stake of 1,112 shares — an estimated $623K sold.

Seven Eight Capital first reported a position in BLUE in Q4 2014 and held it in 9 quarters. The position peaked at $1.72M in Q3 2017. 232 funds tracked by Wall St. Rank hold BLUE as of Q2 2021.

Seven Eight Capital reported no remaining bluebird bio position as of Q2 2021 after selling out during the quarter.
Seven Eight Capital sold 1,112 bluebird bio shares in Q2 2021, an estimated $623K.
Seven Eight Capital first reported a position in bluebird bio in Q4 2014 and held it in 9 quarters.
Seven Eight Capital's bluebird bio position peaked at $1.72M in Q3 2017.
232 funds tracked by Wall St. Rank held bluebird bio as of Q2 2021.

Based on Seven Eight Capital's 13F filing for Q2 2021, filed 13 Aug 2021.